Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

Forecast Ownership Financials Chart

Previous Close

$0.36

52W Range

$0.30 - $3.42

50D Avg

$0.52

200D Avg

$1.43

Market Cap

$16.31M

Avg Vol (3M)

$10.21K

Beta

-1.87

Div Yield

ANEB Company Profile

Anebulo Pharmaceuticals, Inc. is a biotechnology firm currently in the clinical trial phase, committed to devising and introducing treatments for individuals affected by severe cannabinoid poisoning and various forms of substance dependency. Its leading experimental drug, ANEB-001, is a small molecule engineered to counteract cannabinoid receptors, specifically targeting both cannabinoid intoxication and overdose. The company was founded in 2020 and maintains its headquarters in Lakeway, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 07, 2021

Website

ANEB Performance

ANEB Financial Summary

	Jun 25	Jun 24	Jun 23
Revenue	-	-	-
Operating Income	$-9.22M	$-8.31M	$-11.78M
Net Income	$-8.48M	$-8.20M	$-11.73M
EBITDA	$-9.22M	$-8.05M	$-11.78M
Basic EPS	$-0.25	$-0.32	$-0.47
Diluted EPS	$-0.25	$-0.32	$-0.47

Fiscal year ends in Jun 25 | Currency in USD

Peer Comparison

Ticker	Company
WHWK	Whitehawk Therapeutics Inc
CLNN	Clene Inc.
ZNTL	Zentalis Pharmaceuticals, Inc.
PLRX	Pliant Therapeutics, Inc.
TLSA	Tiziana Life Sciences Ltd
IMMX	Immix Biopharma, Inc.
COYA	Coya Therapeutics, Inc.
MGNX	MacroGenics, Inc.
OKYO	OKYO Pharma Limited
ESLA	Estrella Immunopharma, Inc.